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ABSTRACT
Background: The most common cause of hyperthyroidism in areas without iodine deficiency 
is Graves’ disease. There are reports of some hematological alterations in hyperthyroidism. 
This study was designed to measure the hematologic profile in the patients with Graves’ disease 
before and after the treatment. Methods: In this cross-sectional study, 100 patients were selected 
with convenience sampling that diagnosed as autoimmune Graves’ disease in our academic 
endocrinology clinic during 2014-2015. Inclusion criteria included autoimmune hyperthyroidism 
in patients who were referred to this center during the study period. Patients who refused to take 
part in the research, had recent infections disease, malignancies, surgical procedures, severe 
trauma, received immunosuppressive drugs or corticosteroids, high erythrocyte sedimentation 
rate (ESR) values during the last six months, and not responded to treatment with methimazole 
were excluded from the study. The simple sampling technique was used to select the patients. A 
complete blood count (CBC) was taken before and after treatment. The P-value less than 0.05 
was considered as the statistical significance level. All data were analyzed using the Statistical 
Package for the Social Sciences 16.0 (SPSS Inc., Chicago, IL, USA) software. Results: One 
hundred patients with a mean age of 38 ± 9.8 years were included. There were no significant 
changes in the white blood cells (WBC) count, red blood cells (RBC) count, and platelets. Mild 
anemia (Hb=12.16±1.23) present before treating the hyperthyroidism that was significantly 
improved after treatment (P= 0.000). Conclusions: Our results showed that the only significant 
hematologic change in patients with Graves’ disease was mild anemia that improves after treating 
the underlying thyroid disorder.
INTRODUCTION
Hyperthyroidism (Graves’ disease) is an endocrine dis-
order with about 2% prevalence in females and 0.2% in 
males (1-3) and an estimated annual incidence rate of 20 
per 100,000 population (2,3). However, in regions with-
out iodine deficiency, Graves’ disease is the most common 
cause of hyperthyroidism, constitutes about 80% of hyper-
thyroidism cases, while hyperfunctioning autonomous ade-
nomas are the most common cause in regions facing iodine 
deficiency (2,3). Thyroid function disorders are among the 
most common endocrine diseases (4,5). All body tissues 
need thyroid hormones for normal development, differenti-
ation, metabolic balance, and physiological function (4,5). 
Hematological abnormalities have frequently been reported 
in thyroid disorders. Anemia is the most prevalent disorder 
being defined in 20-60% of the patients with hypothyroid-
ism (5). Anemia may occur for several reasons, including 
abnormality of the formation and reduced half lifetime of 
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the red blood cells (RBCs) or increased osmotic fragility of 
RBCs (4).
There are contradictory evidances regarding hemato-
logical parameters in hyperthyroidism (4,6,7). Although 
early reports showed that Graves’ disease is also associat-
ed with hematological disorders, anemia is not frequently 
observed in this group, and erythrocytosis is seen more 
common. Furthermore, hematological parameters most-
ly return to normal when euthyroid state achieved [5], 
although some other studies reported contradictory re-
sults (4,6).
Furthermore, the number of leucocytes may increase, re-
main normal, or may decline slightly when thyroid disorders 
present. A relative reduction in the neutrophils and increase 
in eosinophils and mononuclear cells may be observed in 
hyperthyroidism (8,9). 
Based on the previous studies, there are thyroid stimu-
lating hormone (TSH) receptors on myeloid and lymphoid 
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cells, and these findings support the ability of TSH to influ-
ence the performance of lymphocytes (10). 
Regarding the high prevalence of thyroid disorders in Iran 
(11), this study was designed to measure the hematological 
changes in people with autoimmune hyperthyroidism before 
and after treatment in Gorgan city, Northeast of Iran. 
METHODS
Ethical Considerations
The study protocol was approved by the ethical committee 
of Golestan University of Medical Sciences. Informed con-
sent was taken from all participants. Patients were free to 
leave the study at any stage without influencing their treat-
ment course. 
Study Population
In this cross-sectional study, 100 patients were recruited 
from those referred to the Sayyad-e-Shirazi academic hos-
pital and private clinics in Gorgan city who were diagnosed 
with Graves’ disease during 2013-2014. 
Clinical examination of the thyroid gland, checking blood 
pressure, heartbeat, and the eyes (to find active symptoms of 
Graves’ ophthalmopathy) were done by internal medicine 
specialists and highly specialized endocrinologists. Initial 
complete blood count (CBC) was performed in all patients 
including white blood cell (WBC) count, RBC count, hema-
tocrit (HCT), hemoglobin (Hb), and platelets.
Demographic characteristics of the patients and results 
of their clinical examination have been recorded in a check-
list. 
Inclusion and Exclusion Criteria
Inclusion criteria included autoimmune hyperthyroidism in 
patients who were referred to our center during the study 
period. Patients who refused to take part in the research, had 
recent infection diseases, malignancies, surgical procedures, 
or severe trauma, received immunosuppressive drugs or 
corticosteroids, high erythrocyte sedimentation rate (ESR) 
values during the last six months, and not responded to treat-
ment with methimazole were excluded from the study. The 
simple sampling method was used to select the patients.  
Statistical Analysis
Data analysis was performed using the descriptive and cor-
relation test. The P-value less than 0.05 was considered as a 
minutest value for statistical significance level. All data were 
analyzed using the Statistical Package for the Social Scienc-
es 16.0 (SPSS Inc., Chicago, IL, USA) software.
RESULTS
The mean age of the patients was 38±9.8 years. Eighty-two 
(82%), 15% and 3% of the patients were Fars, Turkmen and 
Sistani ethnicities, respectively.
The mean TSH levels before and after treatment were 
0.06 (0.3) and 2.2 (0.9) mU/L, respectively (P=0.000). 
There were no significant changes in the WBC count after 
treatment with methimazole (P= 0.96). Only three patients 
had WBC count of more than 10,000 before treatment (that 
dropped to below 10,000 after treatment).
The mean Hb level has been significantly raised after 
treatment (P=0.000) Table 1.
There were no considerable changes (requiring treat-
ment) in platelet count of the studied patients with Graves’ 
disease. 
DISCUSSION
Present results indicated mild anemia in about 40% of the 
studied population with Graves’ disease, but no considerable 
reductions in the number of RBC count were observed in this 
study. There has been seen no significant disorders or chang-
es in WBC count or platelet count before and after treatment.
These results have been reported in other studies to some 
extent; some were in agreement with us and other revealed 
different results.
A significantly high prevalence of anemia (40% in 
females with thyroid disorders) has been reported in other 
studies associated with decreased number of RBCs, Hb con-
centration, packed cell volume (PCV), and mean corpuscular 
hemoglobin (MCH).  Microcytic hypochromic and normo-
cytic normochromic anemia were the most common detected 
types of anemia (5).
Anemia was the pioneer of hematologic disorders in oth-
er similar studies. In a study by Gianoukakis et al. on 87 
newly diagnosed Graves’ cases, anemia was reported in 33% 
of subjects. In 22% of all cases, anemia was exclusively 
related to thyroid dysfunction (41.6% of men compared to 
17.5% of women). Antithyroid therapy for about 4 months 
resulted in normalization of Hb levels in 8 out of 9 cases 
(10.7 ± 0.8 g/dl to 13.5 ± 1.3 g/dl) (1).
Regarding the statistically significant difference in RBC 
count, MCH, mean corpuscular hemoglobin concentration 
(MCHC), RBC distribution width (RDW), Hb, and HCT be-
tween hyperthyroid and hypothyroid cases, Dorgalaleh et al. 
suggested evaluating thyroid hormones in patients with un-
known hematological dysfunctions (12).
Jafarzadeh et al. showed a significantly lower mean count 
of RBC and some RBC-related indices (HCT and Hb) in the 
hypothyroid group compared to the euthyroid group. Also, 
the mean MCV was significantly lower in hyperthyroid cas-
es in comparison with the euthyroid group (13). This com-
Table 1. Changes in RBC count, Hb and HCT levels in 
patients with Graves’ disease (before and after treatment)
 Before 
treatment
 After 
treatment
 P-value
RBC count (million/mm3) 4.61±0.53 4.57±0.49 0.299
Hb (g/dl) 12.16±1.23 12.61±1.09 0.000
HCT (%) 38.16±3.87 38.63±3.40 0.057
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parison was not available in our study, and we just enrolled 
Graves’ cases with no control group. 
Limitations of the Study
Our studied population was just included patients with 
Graves’ disease with no controls or hypothyroidism cases 
that could make it a little difficult to expand the results to 
larger populations with different types of thyroid disorders.
CONCLUSIONS
Our results showed that the only significant hematologic 
change in patients with Graves’ disease is mild anemia that 
improves after treating the underlying thyroid disorder. 
ACKNOWLEDGMENT
This paper was extracted from a doctorate thesis dedicated 
to gain MD degree, in Golestan University of Medical Sci-
ences.
AUTHORS CONTRIBUTION
All authors contributed equally in this study.
REFERENCES
1. Gianoukakis AG, Leigh MJ, Richards P, Christenson PD, 
Hakimian A, Fu P, et al. Characterization of the anae-
mia associated with Graves’ disease. Clin Endocrinol 
2009;70(5):781-7.
2. Fumarola A, Di Fiore A, Dainelli M, Grani G, 
Calvanese A. Medical treatment of hyperthyroid-
ism: state of the art. Exp Clin Endocrinol Diabetes. 
2010;118(10):678-84.
3. Dasgupta S, Savage M. Evaluation of manage-
ment of Graves’ disease in district general hospital: 
achievement of consensus guidelines. Int J Clin Pract. 
2005;59(9):1097-100.
4. Zahediasl S, Habibi G, Ghasemi A, Rad SP, Shiva N. 
Hematological parameters and osmotic fragility of red 
blood cells in experimentally induced hyperthyroidism 
in rats. Int J Endocrinol Metab. 2010;8(2):74-8.
5. Refaat B. Prevalence and characteristics of anemia as-
sociated with thyroid disorders in non-pregnant Saudi 
women during the childbearing age: a cross-sectional 
study. Biomed J. 2015;38(4):307.
6. Iddah M, Macharia B, Ng’wena A, Keter A, Ofulla A. 
Thryroid hormones and hematological indices levels in 
thyroid disorders patients at Moi teaching and referral 
hospital, Western Kenya. ISRN endocrinol. 2013;2013.
7. Jafarzadeh A, Poorgholami M, Izadi N, Nemati M, 
Rezayati M. Immunological and hematological chang-
es in patients with hyperthyroidism or hypothyroidism. 
Clin Invest Med. 2010;33(5):271-9.
8. Lima CS, Wittmann DEZ, Castro V, Tambascia MA, Lo-
rand-Metze I, Saad ST, et al. Pancytopenia in untreated pa-
tients with Graves’ disease. Thyroid. 2006;16(4):403-9.
9. Klein JR. Physiological relevance of thyroid stimulat-
ing hormone and thyroid stimulating hormone recep-
tor in tissues other than the thyroid. Autoimmunity. 
2003;36(6-7):417-21.
10. Bağriaçik EÜ, Klein JR. The thyrotropin (thyroid-stim-
ulating hormone) receptor is expressed on murine den-
dritic cells and on a subset of CD45RBhigh lymph 
node T cells: functional role for thyroid-stimulat-
ing hormone during immune activation. J Immunol. 
2000;164(12):6158-65.
11. Aminorroaya A, Janghorbani M, Amini M, Hovsepian S, 
Tabatabaei A, Fallah Z. The prevalence of thyroid dys-
function in an iodine-sufficient area in Iran. Arch Iran 
Med. 2009;12(3):262-70.
12. Dorgalaleh A, Mahmoodi M, Varmaghani B. Effect of 
thyroid dysfunctions on blood cell count and red blood 
cell indice. Iran J Ped Hematol Oncol. 2013;3(2):73.
13. Jafarzadeh A, Poorgholami M, Izadi N, Nemati M, 
Rezayati M. Immunological and hematological chang-
es in patients with hyperthyroidism or hypothyroidism. 
Clin Invest Med. 2010;33(5):271-9.
